Zhejiang Ausun Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 35.61%

Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Income Margin is 35.61% for the year ending December 31, 2023, a 5.63% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 33.71%, a 19.91% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 28.11%, a 19.08% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 23.61%, a 18.95% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 19.85%, a 2.45% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Shanghai Stock Exchange: 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd.

CEO	Mr. Zhiguo Zheng
IPO Date	May 9, 2017
Location	China
Headquarters	No. 5 Donghai Fourth Lane
Employees	1,174
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials

Description

Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it is involved in the processing, and research and development business. The company was founded in 2010 is based in Linhai, China.

Key trends

Past 5 years